Skip to content
DE

TeduglutidePrescription peptide

Teduglutide helps some people with short bowel syndrome absorb more fluid and nutrients. The practical goal is less reliance on support delivered through a vein.

What is Teduglutide?

Teduglutide is a GLP-2 analogue used in short bowel syndrome. EU Revestive is intended for a defined intestinal-failure treatment context. 1

How it works

GLP-2 activity supports the remaining intestine’s capacity to absorb fluid and nutrients.

Effects studied

Reduced parenteral support

Trials assess reductions in the volume or number of days of intravenous nutritional or fluid support. 1 2 3

Evidence: Less support and complete independence are distinct outcomes; response depends on the remaining bowel and clinical situation.

What does the evidence show?

Short bowel syndrome trials and EMA indication

When absorption becomes the limiting factor

After substantial bowel loss, eating enough may not translate into absorbing enough. Some people need intravenous fluid or nutrition to maintain hydration and nutritional status. Teduglutide is a glucagon-like peptide-2 analogue developed for this specific problem.

Helping the bowel do more

GLP-2 signalling supports the intestine’s absorptive capacity. Teduglutide acts on this pathway, helping the remaining bowel take up more fluid and nutrients. It does not replace the missing length of intestine, and the response depends partly on the anatomy and function that remain. 1

What counts as progress

Studies measure reductions in parenteral support while checking that hydration and nutrition remain adequate. Fewer infusion days can matter even when a person still needs support. Complete independence is a separate outcome; reducing weekly volume does not amount to a universal cure.

Why monitoring stays central

Improved absorption can change fluid balance. Bowel obstruction, biliary or pancreatic problems and surveillance for intestinal growths also require attention. The care team needs to reassess nutritional support as the response develops. Teduglutide therefore involves ongoing intestinal rehabilitation and monitoring; its use cannot be extended to ordinary bloating, food sensitivity or digestive discomfort.

Safety & status

Fluid balance, bowel obstruction, biliary and pancreatic problems, and intestinal-growth surveillance are important aspects of treatment. 1

Country and product status

Revestive is authorised in the EU for short bowel syndrome in defined adult and paediatric populations.

Frequently asked questions

Does it regrow a normal-length intestine?

The treatment rationale is improved function of the remaining intestine, not replacement of the removed bowel.

Does reduced intravenous support mean none is needed?

No. A reduction in volume or days can be useful without reaching complete independence. 1

Further reading

Concept illustration for Teduglutide.GuideTeduglutide (Gattex): use, effects and side effectsTeduglutide is used in short bowel syndrome to reduce the need for intravenous nutrition and fluids. How it works, its risks, and why monitoring is needed.Read the article

Sources

This entry was rewritten from our research archive. References below are reading leads unless a completed check is explicitly noted; a full independent evidence and regulatory review is still pending.

  1. EMA · Revestive overview European regulator · Regulator information checked 27 October 2026; indication-specific, not a review of all jurisdictions.
  2. Teduglutide · retained archive reference Archive research lead · Retained archive reference; not independently checked for this draft
  3. Teduglutide · retained archive reference Archive research lead · Retained archive reference; not independently checked for this draft
Research provenance

This name was discovered in the Superpower peptide index, archived 26 October 2026. Its ratings and reviewer attribution have not been adopted as our own. The archive informed this original editorial draft; independent source review is still pending.